Discontinuation report NORPROLAC
| Report ID | 129605 |
| Drug Identification Number | 02223767 |
| Brand name | NORPROLAC |
| Common or Proper name | Quinagolide Hydrochloride |
| Company Name | FERRING INC |
| Market Status | CANCELLED POST MARKET |
| Active Ingredient(s) | QUINAGOLIDE |
| Strength(s) | 0.075MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL ORAL |
| Packaging size | 30 tablets per carton |
| ATC code | G02CB |
| ATC description | OTHER GYNECOLOGICALS |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2020-12-02 |
| Actual discontinuation date | 2020-12-09 |
| Remaining supply date | 2020-12-02 |
| Discontinuation status | Discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | NORPROLAC 150 mcg tablets (DIN 02223767) and NORPROLAC starter pack containing 25 mcg (DIN 02223740) and 50 mcg (DIN 02223759) tablets are in stock and available. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 200 YORKLAND BLVD TORONTO, ONTARIO CANADA M2J 5C1 |
| Company contact information | 1-800-263-4057 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v4 | 2020-12-11 | French | Compare |
| v3 | 2020-12-11 | English | Compare |
| v2 | 2020-12-04 | French | Compare |
| v1 | 2020-12-04 | English | Compare |
Showing 1 to 4 of 4